A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Transcript (slightly modified)
What are some example of countries that have successfully curbed drug prices that the US might want to consider? And would they even work in the US?
I would say that I think the combination of the systems. The structure of the systems in Germany and the United Kingdom but very much adapted for the US model would be an approach that I think could work here. The idea of letting the drug on the market while an assessment is being made, but then let the payers have a notion of what is the value threshold in terms of a cost per quality-adjusted life year, or some other measure of health gain, that is what they are willing to pay for a drug. Because we have a pluralistic system of payers in the United States, it wouldn’t necessarily be the same threshold for every payer.
Already we have a system where Medicare pays one price, Medicaid gets rebates, the Department of Veterans Affairs gets other rebates, and the private sector negotiates its own discounts. So, the different payers could have their different thresholds and be negotiating discounts in return for preferred formulary placement, just as they do right now. But, the whole system could be geared to something that is based off an assessed value so the prices really are based on something that is a measure of actual value delivered in terms of the patient-centric health benefits and the cost saved to the healthcare system. Whereas, at the moment the price is pretty much whatever the manufacturer chooses to name, and that contributes to our unending upward spiral of prices.
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More